Review





Similar Products

99
ATCC dld1 cells human atcc ccl 221 hek293t cells
Dld1 Cells Human Atcc Ccl 221 Hek293t Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dld+1/DLD-1/pm42998979-210-14-17
Average 99 stars, based on 1 article reviews
dld1 cells human atcc ccl 221 hek293t cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

dld1  (ATCC)
99
ATCC dld1
Dld1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dld+1/DLD-1/pm42972081-281-0-15
Average 99 stars, based on 1 article reviews
dld1 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

hct116  (ATCC)
99
ATCC hct116
Hct116, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dld+1/DLD-1/pm42883769-261-7-13
Average 99 stars, based on 1 article reviews
hct116 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC dld 1 ccl 221
Dld 1 Ccl 221, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dld+1/DLD-1/pm42884073-215-8-14
Average 99 stars, based on 1 article reviews
dld 1 ccl 221 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

dld 1  (ATCC)
99
ATCC dld 1
Cell viability graphs of studied cell lines (A: <t>DLD‐1;</t> B: HL‐60 and C: HUVEC cell lines).
Dld 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dld+1/DLD-1/pmc13670403-161-5-8
Average 99 stars, based on 1 article reviews
dld 1 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC dld 1 colorectal adenocarcinoma cells
a Gene set enrichment analysis of RNA-seq data showing the top 5 upregulated and downregulated pathways in MDA5 knockout MC38 cells compared with control, n = 1 control and n = 2 MDA5 KO . b Gene set enrichment analysis of the unfolded protein response signature in MDA5 knockout cells compared with control MC38 cells, n = 1 control and n = 2 MDA5 KO . Levels of extracellular ATP ( c ) or secreted HMGB1 ( d ) in the conditioned medium (CM) of 10 6 control or MDA5 knockout MC38, Hepa1-6, HCT-15 and <t>DLD-1</t> cells after treatment with indicated treatments. Data are presented as mean ± SD and n = 3 independent experiments. e Flow cytometry analysis of surface-exposed calreticulin level of MC38, Hepa1-6, HCT-15 and DLD-1 cells after treated with indicated treatments. n = 3 independent experiments. Tumor growth curves ( f ) and tumor weights ( g ) from C57BL/6 mice implanted with control, MDA5 knockout MC38 cells. These mice were treated with or without HMGB1-neutralizing antibody and the P2X7 receptor antagonist A438079. Data are presented as mean ± SEM ( f ) and mean ± SD ( g ), n = 10 tumors/group. h–i A scatter plot showing the correlation between the MDA5-null signature and DAMPs signature, ICD signature or DC activation signature in the E-MTAB-12862 dataset and the TCGA-COADREAD dataset. n = 1063 cases. j Boxplots illustrating the signature score of the DAMPs, ICD and DC activation in the MDA5 wild-type ( n = 1021) and MDA5 loss-of-function (LOF, n = 23) groups, analyzed using the colorectal cancer dataset (E-MTAB-12862). The center line indicates the median, box bounds indicate the 25th and 75th percentiles, and whiskers represent the minimum and maximum values. Statistics were applied using one-sided empirical permutation test with Benjamini–Hochberg adjustment ( a , b ), two-way ANOVA with Tukey’s multiple comparisons test ( c , d , f , g ); two-sided Pearson correlation test ( h , i ); or two-sided Wilcoxon rank-sum test ( j ). Source data are provided as a Source Data file.
Dld 1 Colorectal Adenocarcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dld+1/DLD-1/pmc13745573-350-36-40
Average 99 stars, based on 1 article reviews
dld 1 colorectal adenocarcinoma cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human crc cell lines dld 1 ccl 221
a Gene set enrichment analysis of RNA-seq data showing the top 5 upregulated and downregulated pathways in MDA5 knockout MC38 cells compared with control, n = 1 control and n = 2 MDA5 KO . b Gene set enrichment analysis of the unfolded protein response signature in MDA5 knockout cells compared with control MC38 cells, n = 1 control and n = 2 MDA5 KO . Levels of extracellular ATP ( c ) or secreted HMGB1 ( d ) in the conditioned medium (CM) of 10 6 control or MDA5 knockout MC38, Hepa1-6, HCT-15 and <t>DLD-1</t> cells after treatment with indicated treatments. Data are presented as mean ± SD and n = 3 independent experiments. e Flow cytometry analysis of surface-exposed calreticulin level of MC38, Hepa1-6, HCT-15 and DLD-1 cells after treated with indicated treatments. n = 3 independent experiments. Tumor growth curves ( f ) and tumor weights ( g ) from C57BL/6 mice implanted with control, MDA5 knockout MC38 cells. These mice were treated with or without HMGB1-neutralizing antibody and the P2X7 receptor antagonist A438079. Data are presented as mean ± SEM ( f ) and mean ± SD ( g ), n = 10 tumors/group. h–i A scatter plot showing the correlation between the MDA5-null signature and DAMPs signature, ICD signature or DC activation signature in the E-MTAB-12862 dataset and the TCGA-COADREAD dataset. n = 1063 cases. j Boxplots illustrating the signature score of the DAMPs, ICD and DC activation in the MDA5 wild-type ( n = 1021) and MDA5 loss-of-function (LOF, n = 23) groups, analyzed using the colorectal cancer dataset (E-MTAB-12862). The center line indicates the median, box bounds indicate the 25th and 75th percentiles, and whiskers represent the minimum and maximum values. Statistics were applied using one-sided empirical permutation test with Benjamini–Hochberg adjustment ( a , b ), two-way ANOVA with Tukey’s multiple comparisons test ( c , d , f , g ); two-sided Pearson correlation test ( h , i ); or two-sided Wilcoxon rank-sum test ( j ). Source data are provided as a Source Data file.
Human Crc Cell Lines Dld 1 Ccl 221, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dld+1/DLD-1/10__3390_slash_molecules31203606-51-18-31
Average 99 stars, based on 1 article reviews
human crc cell lines dld 1 ccl 221 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


Cell viability graphs of studied cell lines (A: DLD‐1; B: HL‐60 and C: HUVEC cell lines).

Journal: Chemistry & Biodiversity

Article Title: Biological Activities and Phytochemical Composition of Arum rupicola var. rupicola : An In Vitro and In Silico Study

doi: 10.1002/cbdv.71785

Figure Lengend Snippet: Cell viability graphs of studied cell lines (A: DLD‐1; B: HL‐60 and C: HUVEC cell lines).

Article Snippet: Cytotoxicity studies were conducted using DLD‐1 (colon carcinoma; ATCC CVCL_0248), HUVEC (normal endothelial; ATCC CCVL_2959), and HL‐60 (leukemia; ATCC CVCL_0002) cell lines.

Techniques:

Selectivity indices of the extracts against the cell lines.

Journal: Chemistry & Biodiversity

Article Title: Biological Activities and Phytochemical Composition of Arum rupicola var. rupicola : An In Vitro and In Silico Study

doi: 10.1002/cbdv.71785

Figure Lengend Snippet: Selectivity indices of the extracts against the cell lines.

Article Snippet: Cytotoxicity studies were conducted using DLD‐1 (colon carcinoma; ATCC CVCL_0248), HUVEC (normal endothelial; ATCC CCVL_2959), and HL‐60 (leukemia; ATCC CVCL_0002) cell lines.

Techniques:

a Gene set enrichment analysis of RNA-seq data showing the top 5 upregulated and downregulated pathways in MDA5 knockout MC38 cells compared with control, n = 1 control and n = 2 MDA5 KO . b Gene set enrichment analysis of the unfolded protein response signature in MDA5 knockout cells compared with control MC38 cells, n = 1 control and n = 2 MDA5 KO . Levels of extracellular ATP ( c ) or secreted HMGB1 ( d ) in the conditioned medium (CM) of 10 6 control or MDA5 knockout MC38, Hepa1-6, HCT-15 and DLD-1 cells after treatment with indicated treatments. Data are presented as mean ± SD and n = 3 independent experiments. e Flow cytometry analysis of surface-exposed calreticulin level of MC38, Hepa1-6, HCT-15 and DLD-1 cells after treated with indicated treatments. n = 3 independent experiments. Tumor growth curves ( f ) and tumor weights ( g ) from C57BL/6 mice implanted with control, MDA5 knockout MC38 cells. These mice were treated with or without HMGB1-neutralizing antibody and the P2X7 receptor antagonist A438079. Data are presented as mean ± SEM ( f ) and mean ± SD ( g ), n = 10 tumors/group. h–i A scatter plot showing the correlation between the MDA5-null signature and DAMPs signature, ICD signature or DC activation signature in the E-MTAB-12862 dataset and the TCGA-COADREAD dataset. n = 1063 cases. j Boxplots illustrating the signature score of the DAMPs, ICD and DC activation in the MDA5 wild-type ( n = 1021) and MDA5 loss-of-function (LOF, n = 23) groups, analyzed using the colorectal cancer dataset (E-MTAB-12862). The center line indicates the median, box bounds indicate the 25th and 75th percentiles, and whiskers represent the minimum and maximum values. Statistics were applied using one-sided empirical permutation test with Benjamini–Hochberg adjustment ( a , b ), two-way ANOVA with Tukey’s multiple comparisons test ( c , d , f , g ); two-sided Pearson correlation test ( h , i ); or two-sided Wilcoxon rank-sum test ( j ). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Targeting MDA5 induces immunogenic cell death and promotes anti-tumor immunity

doi: 10.1038/s41467-026-78587-6

Figure Lengend Snippet: a Gene set enrichment analysis of RNA-seq data showing the top 5 upregulated and downregulated pathways in MDA5 knockout MC38 cells compared with control, n = 1 control and n = 2 MDA5 KO . b Gene set enrichment analysis of the unfolded protein response signature in MDA5 knockout cells compared with control MC38 cells, n = 1 control and n = 2 MDA5 KO . Levels of extracellular ATP ( c ) or secreted HMGB1 ( d ) in the conditioned medium (CM) of 10 6 control or MDA5 knockout MC38, Hepa1-6, HCT-15 and DLD-1 cells after treatment with indicated treatments. Data are presented as mean ± SD and n = 3 independent experiments. e Flow cytometry analysis of surface-exposed calreticulin level of MC38, Hepa1-6, HCT-15 and DLD-1 cells after treated with indicated treatments. n = 3 independent experiments. Tumor growth curves ( f ) and tumor weights ( g ) from C57BL/6 mice implanted with control, MDA5 knockout MC38 cells. These mice were treated with or without HMGB1-neutralizing antibody and the P2X7 receptor antagonist A438079. Data are presented as mean ± SEM ( f ) and mean ± SD ( g ), n = 10 tumors/group. h–i A scatter plot showing the correlation between the MDA5-null signature and DAMPs signature, ICD signature or DC activation signature in the E-MTAB-12862 dataset and the TCGA-COADREAD dataset. n = 1063 cases. j Boxplots illustrating the signature score of the DAMPs, ICD and DC activation in the MDA5 wild-type ( n = 1021) and MDA5 loss-of-function (LOF, n = 23) groups, analyzed using the colorectal cancer dataset (E-MTAB-12862). The center line indicates the median, box bounds indicate the 25th and 75th percentiles, and whiskers represent the minimum and maximum values. Statistics were applied using one-sided empirical permutation test with Benjamini–Hochberg adjustment ( a , b ), two-way ANOVA with Tukey’s multiple comparisons test ( c , d , f , g ); two-sided Pearson correlation test ( h , i ); or two-sided Wilcoxon rank-sum test ( j ). Source data are provided as a Source Data file.

Article Snippet: CT26 colon adenocarcinoma cells (ATCC, Cat# CRL-2638, RRID: CVCL_7256), B16-F10 melanoma cells (ATCC, Cat# CRL-6475, RRID: CVCL_0159), Hepa1-6 Hepatocellular carcinoma cells (ATCC, Cat# CRL-1830, RRID: CVCL_0327), HCT-15 colorectal cancer cells (ATCC, Cat# CCL-225, RRID: CVCL_0292) and DLD-1 colorectal adenocarcinoma cells (ATCC, Cat# CCL-221, RRID: CVCL_0248) were purchased from ATCC.

Techniques: Gene Set Enrichment Analysis, RNA Sequencing, Knock-Out, Control, Flow Cytometry, Analysis, Activation Assay

a Schematic overview of the in vivo competition assay. b–c Tumor growth curves and cell proportion of Control-GFP+ and MDA5 KO -mCherry+ MC38 cells at different time points after tumor inoculation into immunocompetent mice ( b ) or immunodeficient mice ( c ). n = 6 tumors per point. Illustration of tumor-T cell co-culture experiment performed in Transwell ( d ) and the representative FACS results showing the ratio of MDA5 knockout and control cells in the upper and lower chambers upon the addition of OT-I T cells ( e ), n = 3 independent experiments. f Log2 transformed relative cell viability for MDA5 knockout cells after treated with IFN-γ, TNF-α, or their combination ( n = 3 independent experiments). g Log2 transformed relative cell viability for MDA5 single knockout, or MDA5-TNFR1-IFNGR1 triple knockout MC38 cells after treated with IFN-γ and TNF-α ( n = 6 independent experiments). h WB analysis of MDA5, p-ASK1, ASK1, p-JNK, JNK, p-p38, p38 in MC38 and DLD-1 tumor cells after the indicated treatment. Representative images from three independent experiments. Log2 transformed relative cell viability of MDA5 knockout MC38-OVA cells after treatment with the combination of IFN-γ and TNF-α ( i ) or co-cultured with OT-I Cells ( j ), either in the presence or absence of GS-4997 ( n = 6 independent samples for control, IFN-γ + TNF-α, and OT-I treatments; n = 3 for presence of GS-4997). Tumor growth curves ( k ) and tumors ( l ) for MC38 control or MDA5 knockout tumors in immunocompetent C57BL/6 mice treated with or without JNK and p38 inhibitors. ( n = 8 tumors/group). Tumor growth curves ( m ) and tumor weight ( n ) for Ctrl, Ctrl-TNFR1 KO - IFNGR1 KO , MDA5 KO and MDA5 KO - TNFR1 KO - IFNGR1 KO MC38 tumors in immunocompetent C57BL/6 mice. ( n = 10 tumors/group). Data are presented as the mean ± SEM in ( b , k , m ), and mean ± SD in ( c , f , g , i , j , n ). Statistics were applied using two-way ANOVA with Tukey’s multiple comparisons test ( f , g , i–n ). Created in BioRender. Zhitong, N. (2026) https://BioRender.com/pvldmia ( a , d ). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Targeting MDA5 induces immunogenic cell death and promotes anti-tumor immunity

doi: 10.1038/s41467-026-78587-6

Figure Lengend Snippet: a Schematic overview of the in vivo competition assay. b–c Tumor growth curves and cell proportion of Control-GFP+ and MDA5 KO -mCherry+ MC38 cells at different time points after tumor inoculation into immunocompetent mice ( b ) or immunodeficient mice ( c ). n = 6 tumors per point. Illustration of tumor-T cell co-culture experiment performed in Transwell ( d ) and the representative FACS results showing the ratio of MDA5 knockout and control cells in the upper and lower chambers upon the addition of OT-I T cells ( e ), n = 3 independent experiments. f Log2 transformed relative cell viability for MDA5 knockout cells after treated with IFN-γ, TNF-α, or their combination ( n = 3 independent experiments). g Log2 transformed relative cell viability for MDA5 single knockout, or MDA5-TNFR1-IFNGR1 triple knockout MC38 cells after treated with IFN-γ and TNF-α ( n = 6 independent experiments). h WB analysis of MDA5, p-ASK1, ASK1, p-JNK, JNK, p-p38, p38 in MC38 and DLD-1 tumor cells after the indicated treatment. Representative images from three independent experiments. Log2 transformed relative cell viability of MDA5 knockout MC38-OVA cells after treatment with the combination of IFN-γ and TNF-α ( i ) or co-cultured with OT-I Cells ( j ), either in the presence or absence of GS-4997 ( n = 6 independent samples for control, IFN-γ + TNF-α, and OT-I treatments; n = 3 for presence of GS-4997). Tumor growth curves ( k ) and tumors ( l ) for MC38 control or MDA5 knockout tumors in immunocompetent C57BL/6 mice treated with or without JNK and p38 inhibitors. ( n = 8 tumors/group). Tumor growth curves ( m ) and tumor weight ( n ) for Ctrl, Ctrl-TNFR1 KO - IFNGR1 KO , MDA5 KO and MDA5 KO - TNFR1 KO - IFNGR1 KO MC38 tumors in immunocompetent C57BL/6 mice. ( n = 10 tumors/group). Data are presented as the mean ± SEM in ( b , k , m ), and mean ± SD in ( c , f , g , i , j , n ). Statistics were applied using two-way ANOVA with Tukey’s multiple comparisons test ( f , g , i–n ). Created in BioRender. Zhitong, N. (2026) https://BioRender.com/pvldmia ( a , d ). Source data are provided as a Source Data file.

Article Snippet: CT26 colon adenocarcinoma cells (ATCC, Cat# CRL-2638, RRID: CVCL_7256), B16-F10 melanoma cells (ATCC, Cat# CRL-6475, RRID: CVCL_0159), Hepa1-6 Hepatocellular carcinoma cells (ATCC, Cat# CRL-1830, RRID: CVCL_0327), HCT-15 colorectal cancer cells (ATCC, Cat# CCL-225, RRID: CVCL_0292) and DLD-1 colorectal adenocarcinoma cells (ATCC, Cat# CCL-221, RRID: CVCL_0248) were purchased from ATCC.

Techniques: In Vivo, Competitive Binding Assay, Control, Tumor Implantation, Co-culture Assay, Knock-Out, Transformation Assay, Triple Knockout, Analysis, Cell Culture, Co-Culture, FACS